United Therapeutics reported that its phase 3 ADVANCE OUTCOMES study of ralinepag met its primary endpoint, showing a 55% reduction in the risk of clinical worsening compared with placebo. The hazard ratio was 0.45, with a 95% confidence interval of 0.33‑0.62 and a p‑value of less than 0.0001, based on data from 687 patients.
Secondary endpoints also reached statistical significance. The odds of clinical improvement increased by 47%, the six‑minute walk distance improved, and N‑terminal pro‑B‑type natriuretic peptide levels fell. The study population was heavily treated, with 80% on dual background therapy and 70% in WHO/NYHA Functional Class II at baseline, underscoring the benefit across a broad patient group.
Ralinepag is a once‑daily oral prostacyclin receptor agonist that mimics the steady‑state exposure of parenteral therapy. “With its extended‑release profile and pharmacokinetic characteristics that mimic the steady‑state exposure of parenteral therapy, ralinepag provides disease‑mitigating capabilities that target underlying PAH pathology and achieve impressive clinical benefits,” said Derek Solum, Senior Director, Product Development at United Therapeutics.
The results position ralinepag as a potentially transformative therapy for pulmonary arterial hypertension, a disease that currently relies on intravenous or inhaled treatments that do not reverse disease progression. “PAH is a progressive, life‑threatening disease that has a devastating impact on patients' lives. In the ADVANCE OUTCOMES study, ralinepag delayed disease progression in patients with PAH facing significant disease burden at baseline. Ralinepag's potency and once‑daily oral dosing make these outcomes highly relevant in real‑world settings,” said Vallerie V. McLaughlin, MD, Professor of Cardiovascular Medicine at the University of Michigan.
United Therapeutics already markets Tyvaso, Tyvaso DPI, Remodulin, and Orenitram. The new data give the company a competitive edge against rivals such as Merck’s Winrevair, Johnson & Johnson’s Opsynvi and Uptravi, and Gilead’s Letairis. The once‑daily oral dosing could give ralinepag a clear advantage over twice‑daily or inhaled therapies.
The company plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026. Management expressed confidence that the data support prompt use of the molecule as a first‑line treatment. “The outcome is better than the results of any other trial of a prostacyclin or a pill, and the data support the prompt use of the molecule as a first‑line treatment,” said Martine Rothblatt, Ph.D., CEO of United Therapeutics. She added that ralinepag could be given to “tens of thousands of patients” because of its consistent benefits across subgroups.
United’s Q4 2025 earnings, released February 25 2026, showed total revenue of $790 million, a 7% increase from Q4 2024, and earnings per share of $7.70, beating analyst estimates of $7.10. The company’s first‑time $3 billion revenue milestone and its guidance for a $4 billion run rate by 2027 demonstrate the financial strength that will support future product launches.
Investors reacted positively to the announcement, reflecting confidence in the drug’s potential to reshape the PAH market and in United’s robust pipeline and financial position.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.